|
|
|
|
|
Palonosetron
drug data and news
Palonosetron drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Palonosetron | ||
| Brand Names/Synonyms | Aloxi; Onicit; Palonosetron; Raloxifene | ||
| Indication | For the treatment of aausea and vomiting associated with cancer chemotherapy | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Palonosetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative nausea and vomiting. Palonosetron is a highly specific and selective serotonin 5-HT3 receptor antagonist, not shown to have activity at other known serotonin receptors and with low affinity for dopamine receptors. | ||
| Mechanism Of Action | Palonosetron is a selective serotonin 5-HT3 receptor antagonist. The serotonin 5-HT3 receptors are located on the nerve terminals of the vagus in the periphery and centrally in the chemoreceptor trigger zone of the area postrema. It is thought that chemotherapeutic agents produce nausea and vomiting by releasing serotonin from the enterochromaffin cells of the small intestine, and that the released serotonin then activates 5-HT3 receptors located on vagal efferents to initiate the vomiting reflex. Therefore Palonosetron works by blocking the reception of serotonin at these 5-HT3 receptors. | ||
| Palonosetron News (When available) |
AP Pharma Reports 2006 First Quarter Results; Phase 3 Clinical ... May 10, 2006 AbelsonTaylor Announces Four New Appointments May 11, 2006 MGI PHARMA to Present at the 2006 Bank of America Health Care ... May 11, 2006 US FDA Approves Dacogen(TM) (Decitabine) For Injection May 3, 2006 US FDA Approves Dacogen(TM) (Decitabine) for Injection; Dacogen(TM ... May 3, 2006 MGI PHARMA Announces Publication of Phase 3 Data for Dacogen ... Apr 18, 2006 MGI PHARMA Reports First Quarter 2006 Financial Results; First ... Apr 19, 2006 | ||
| Dosage Forms | Not Available | ||
| Drug_Category | Antiemetics; ATC:A04AA | ||
| Absorption | Not Available | ||
| Interactions |
-->Interactions for Palonosetron: Palonosetron is eliminated from the body through both renal excretion and metabolic pathways. Therefore, the potential for clinically significant drug interactions with palonosetron appears to be low. | ||
| Toxicity | Not Available | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | Not Available | ||
| Chemical Formula | C19H24N2O | ||
| Molecular Weight | 296.407 g/mol | ||
| Smiles String | C1CC2CN(C(=O)C3=C2C(=CC=C3)C1)C4CN5CCC4CC5 | ||
| Melting Point | Not Available | ||
| Water Solubility | Not Available | ||
| State | Solid | ||
| LogP/Hphobicity | 2.453 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Not Available | ||
| Half Life | Approximately 40 hours | ||
| Protein Binding [%] | 62% | ||
| RxList Link | Not Available>RXlist | ||
| Sponsored links | |||
| Drug Reference | http://www.drugs.com/cons/Palonosetron.html | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00351 | ||
| CAS Registry Number | 119904-90-4 | ||
| KEGG Compound ID | Not Available | ||
| PubChem ID | SID:725898 | ||
| PharmGKB ID | PA10352 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | Not Available |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |